Next Article in Journal
The DNA Methylation Marker ZNF671 Has Prognostic Value for Progressing Cervical Intraepithelial Neoplasia
Previous Article in Journal
Single-Fraction SBRT for Locally Advanced Pancreatic Cancer Using Total Intravenous Anaesthesia and Optical Surface Guidance: Technique and Preliminary Results
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 17
Issue 19
10.3390/cancers17193094
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Cancers 2020, 12(7), 1935.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935

by
Emeline Tabouret
1,2,*,†,
Herui Wang
1,†,
Niranjana Amin
3,
Jinkyu Jung
1,
Romain Appay
2,
Jing Cui
1,
Qi Song
1,
Antonio Cardone
4,
Deric M. Park
5,
Mark R. Gilbert
1,
Harish Pant
3 and
Zhengping Zhuang
1,*
1
Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
2
Team 8 GlioME, CNRS, INP, Inst Neurophysiopathol, Aix-Marseille University, 13005 Marseille, France
3
Neuronal Cytoskeletal Protein Regulation Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD 20824, USA
4
University of Maryland Institute for Advanced Computer Studies, College Park, MD 20742, USA
5
Department of Neurology and the Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago, Chicago, IL 60637, USA
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2025, 17(19), 3094; https://doi.org/10.3390/cancers17193094
Submission received: 15 September 2025 / Accepted: 17 September 2025 / Published: 23 September 2025
Browse Figure
Versions Notes
In the original publication [1], there was a mistake in Figure 2B-LN229 as published. An unintentional error occurred during the cropping of the six-well plate images used to display individual wells for the LN229-1 µM and 10 µM conditions. The corrected Figure 2B-LN229 appears below. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Tabouret, E.; Wang, H.; Amin, N.; Jung, J.; Appay, R.; Cui, J.; Song, Q.; Cardone, A.; Park, D.M.; Gilbert, M.R.; et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935. [Google Scholar] [CrossRef] [PubMed]
Cancers 17 03094 g002
Figure 2. TP5 decreases cell viability by inducing cell apoptosis. (A) Viability of U251, LN229, U87 and T98G cells treated by indicated concentrations of TP5 or scrambled peptide for 72 h is shown (*** p > 0.001). Right table: IC50 concentrations. (B) Clonogenic growth of U251 (top panels) and LN229 (bottom panels) cells is shown. The bar graphs display quantification of colonies under treatment at indicated concentrations (N = 3) (* p < 0.05; *** p < 0.001). (C) Apoptosis analysis by Annexin V/Propidium Iodide (PI) staining. Left panel: Representative flow cytometry dot plot graphs of annexin V and PI in U251 cells are shown. The bar graph displays the quantification of early (Q3) and late (Q2) apoptotic cells after treatment by TP5 (25 µM) in U251 cells (N = 4) (*** p < 0.001). Right panel shows protein level of cleaved PARP and cleaved Caspase 3 in U251 cells after 24 h of treatment by TP5 (25 µM). (D) Apoptosis analysis in LN229 cells. Left panel: Representative flow cytometry dot plot graphs of annexin V and PI in LN229 cells are shown. The bar graph displays the quantification of early and late apoptotic cells after treatment by TP5 (25 µM) in LN229 cells (N = 4; ** p < 0.01; *** p < 0.001). Right panel shows protein level of cleaved PARP and cleaved Caspase 3 in LN229 cells after 24 h of treatment by TP5 (25 µM).
Figure 2. TP5 decreases cell viability by inducing cell apoptosis. (A) Viability of U251, LN229, U87 and T98G cells treated by indicated concentrations of TP5 or scrambled peptide for 72 h is shown (*** p > 0.001). Right table: IC50 concentrations. (B) Clonogenic growth of U251 (top panels) and LN229 (bottom panels) cells is shown. The bar graphs display quantification of colonies under treatment at indicated concentrations (N = 3) (* p < 0.05; *** p < 0.001). (C) Apoptosis analysis by Annexin V/Propidium Iodide (PI) staining. Left panel: Representative flow cytometry dot plot graphs of annexin V and PI in U251 cells are shown. The bar graph displays the quantification of early (Q3) and late (Q2) apoptotic cells after treatment by TP5 (25 µM) in U251 cells (N = 4) (*** p < 0.001). Right panel shows protein level of cleaved PARP and cleaved Caspase 3 in U251 cells after 24 h of treatment by TP5 (25 µM). (D) Apoptosis analysis in LN229 cells. Left panel: Representative flow cytometry dot plot graphs of annexin V and PI in LN229 cells are shown. The bar graph displays the quantification of early and late apoptotic cells after treatment by TP5 (25 µM) in LN229 cells (N = 4; ** p < 0.01; *** p < 0.001). Right panel shows protein level of cleaved PARP and cleaved Caspase 3 in LN229 cells after 24 h of treatment by TP5 (25 µM).
Cancers 17 03094 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Tabouret, E.; Wang, H.; Amin, N.; Jung, J.; Appay, R.; Cui, J.; Song, Q.; Cardone, A.; Park, D.M.; Gilbert, M.R.; et al. Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935. Cancers 2025, 17, 3094. https://doi.org/10.3390/cancers17193094

AMA Style

Tabouret E, Wang H, Amin N, Jung J, Appay R, Cui J, Song Q, Cardone A, Park DM, Gilbert MR, et al. Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935. Cancers. 2025; 17(19):3094. https://doi.org/10.3390/cancers17193094

Chicago/Turabian Style

Tabouret, Emeline, Herui Wang, Niranjana Amin, Jinkyu Jung, Romain Appay, Jing Cui, Qi Song, Antonio Cardone, Deric M. Park, Mark R. Gilbert, and et al. 2025. "Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935" Cancers 17, no. 19: 3094. https://doi.org/10.3390/cancers17193094

APA Style

Tabouret, E., Wang, H., Amin, N., Jung, J., Appay, R., Cui, J., Song, Q., Cardone, A., Park, D. M., Gilbert, M. R., Pant, H., & Zhuang, Z. (2025). Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935. Cancers, 17(19), 3094. https://doi.org/10.3390/cancers17193094

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop